Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$25.55
$0.60(2.35%)
At close: 4:00 PM EDT
$25.55
$0.60(2.35%)
Day’s Range― - ―
52-Week Range$20.23 - $39.71
Previous CloseN/A
Volume1.34K
Average Volume (3M)164.41K
Market Cap
$593.53M
Enterprise Value$200.09
Total Cash (Recent Filing)$320.36M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)59.9
Beta1.31
Next Earnings
Nov 11, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding19,817,250
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.00Price Target Upside80.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$45.52M
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetVery low leverage and a sizable equity base provide durable financial flexibility. With ~ $2.5M debt versus nearly $199M equity and ~ $235.5M in assets, the company can fund near-term R&D and clinical programs with lower default risk and greater ability to structure partnerships or licenses without urgent debt pressure.
Completed $107.4M Equity FinancingA sizable institutional-backed equity raise materially extends runway for clinical development and lowers immediate refinancing risk. The deal included healthcare investors (including Gilead participation), lock-ups and underwriter support, improving funding capacity and optionality to advance trials without immediate commercialization revenue.
Pipeline Expansion: ABI-6250 Into Cholestatic Liver DiseasesExtending ABI-6250 into PBC and PSC and scheduling Phase 2 studies represents a structural broadening of addressable indications. Targeting high unmet-need, differentiable oral NTCP mechanism and positive pre-IND FDA discussions increase the program's strategic optionality and potential for multiple late-stage value inflection points.
Bears Say
High Cash Burn And Negative FCFSustained negative operating and free cash flow of roughly -$39.8M TTM, with sharply worsening FCF growth, indicates the business is consuming capital rather than generating it. This persistent burn creates structural reliance on external financing and increases dilution or financing risk if trial timelines or costs extend.
Negative Profitability And Volatile RevenueVolatile top-line (large year-over-year decline) combined with ongoing negative margins shows the company has not achieved stable commercial economics. Continued negative profitability reduces internal cash generation, limits reinvestment capacity, and makes long-term planning dependent on successful clinical outcomes rather than recurring revenue streams.
No Product Revenue; Reliant On Partnerships And Capital RaisesThe company lacks commercial product sales and depends on collaborations, milestone/licensing payments and equity financings. That structural model leaves funding and program continuity exposed to partner interest and capital markets access; long-term viability hinges on clinical success and sustained external funding availability.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $20.23 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $593.53M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.524.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.7.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 19,817,250 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 10.017%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (80.04% Upside)
$46.00 (80.04% Upside)
Blogger Sentiment
Neutral
ASMB Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $674.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.4%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
137.85%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$46.00
▲(80.04% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
27.13% Insiders
3.79% Mutual Funds
26.32% Other Institutional Investors
37.31% Public Companies and
Individual Investors